Amarin Corporation Plc (AMRN) has disclosed a new risk, in the Competition category.
Amarin Corporation Plc faces a substantial business risk in the United States due to the increasing competition from generic drug companies. Since the ANDA litigation ruling, generic versions of VASCEPA have been launched, leading to a potential ongoing reduction in revenue and operational results. Despite Amarin’s endeavors to defend its intellectual property rights for VASCEPA, the ubiquity of generic alternatives in pharmacies could further diminish its market share. The company’s recent restructuring efforts, including significant workforce reductions, aim to mitigate financial pressures but may concurrently affect morale and operational capabilities.
Overall, Wall Street has a Moderate Sell consensus rating on AMRN stock based on 1 Sell and 1 Hold.
To learn more about Amarin Corporation Plc’s risk factors, click here.
